Direct oral anticoagulants‐Remove versus Taipan snake venom time for detection of a lupus anticoagulant in patients taking oral direct factor Xa inhibitors

Article


White, D., Moore, G., Besser, M., MacDonald, S. and Thomas, W. 2022. Direct oral anticoagulants‐Remove versus Taipan snake venom time for detection of a lupus anticoagulant in patients taking oral direct factor Xa inhibitors. Research and Practice in Thrombosis and Haemostasis. 6 (1), pp. 1-8. https://doi.org/10.1002/rth2.12648
TypeArticle
TitleDirect oral anticoagulants‐Remove versus Taipan snake venom time for detection of a lupus anticoagulant in patients taking oral direct factor Xa inhibitors
AuthorsWhite, D., Moore, G., Besser, M., MacDonald, S. and Thomas, W.
Abstract

Background: The optimal method of detecting a lupus anticoagulant (LA) for patients taking direct factor Xa inhibitor (DFXaI) direct oral anticoagulants (DOACs) remains controversial. Methods include charcoal adsorption of the DOACs to allow testing with the activated partial thromboplastin time (APTT) and dilute Russell viper venom time (dRVVT), or use of the DFXaI‐insensitive Taipan snake venom time (TSVT) and Ecarin time (ET) assays on neat plasma. Objectives: The objective was to compare the utility of APTT and dRVVT analysis following DOAC Remove against TSVT/ET on untreated plasma for LA detection in spiked plasmas and routine clinical samples for patients on DFXaIs. Patients/methods: Various LA‐negative and LA‐positive samples were assayed by APTT, dRVVT, and TSVT/ET, and then separately spiked with rivaroxaban, apixaban, and edoxaban calibrators to a concentration of ~190 ng/ml and the assays repeated on spiked plasma before and after DOAC Remove treatment. Testing of 284 consecutive samples from DFXaI‐anticoagulated patients by APTT/dRVVT and TSVT/ET before and after DOAC Remove treatment was undertaken. Results: In the spiking model, we found that both TSVT/ET and DOAC Remove strategies generally distinguished LA‐negative and LA‐positive samples, but some false‐positive LA results occurred. In the investigation of 284 consecutive patient samples on DFXaIs, the percentage agreement for LA detection in neat samples tested by TSVT/ET versus APTT and dRVVT after DOAC Remove treatment was 90% (Cohen kappa 0.12). Conclusion: Our data highlight uncertainty and disagreement for testing LA in patients on DFXaI. Further studies are required.

KeywordsORIGINAL ARTICLE, antiphospholipid syndrome, charcoal adsorption, DOAC Remove™, factor Xa inhibitor, lupus anticoagulant, Taipan snake venom time
PublisherWiley
JournalResearch and Practice in Thrombosis and Haemostasis
ISSN2475-0379
Electronic2475-0379
Publication dates
Online23 Jan 2022
Print23 Jan 2022
Publication process dates
Deposited24 Jan 2022
Accepted24 Nov 2021
Output statusPublished
Publisher's version
License
Copyright Statement

© 2022 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH).
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Digital Object Identifier (DOI)https://doi.org/10.1002/rth2.12648
LanguageEnglish
Permalink -

https://repository.mdx.ac.uk/item/89q56

Download files

  • 107
    total views
  • 135
    total downloads
  • 3
    views this month
  • 9
    downloads this month

Export as

Related outputs

Diagnosing thrombophilia: the case for genetic or functional testing?
Favaloro, E.J., Moore, G.W. and Pasalic, L. 2025. Diagnosing thrombophilia: the case for genetic or functional testing? Expert Review of Molecular Diagnostics. 25 (12), pp. 841-846. https://doi.org/10.1080/14737159.2025.2588621
Survey on current practice in thrombophilia testing: from phenotype to genotype. Communication from the SSC of the ISTH
Van Laer, C., Moore, G.W., Majumder, R., Corral, J., Freson, K., Ignjatovic, V. and Orlando, C. 2025. Survey on current practice in thrombophilia testing: from phenotype to genotype. Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2025.10.032
International Council for Standardization in Haematology (ICSH) recommendations for the performance and interpretation of activated partial thromboplastin time and prothrombin time mixing tests
Adcock, D.M., Moore, G., Kershaw, G.W., Montalvao, S. and Gosselin, R. 2024. International Council for Standardization in Haematology (ICSH) recommendations for the performance and interpretation of activated partial thromboplastin time and prothrombin time mixing tests. International Journal of Laboratory Hematology. 46 (5), pp. 777-788. https://doi.org/10.1111/ijlh.14344
International Council for Standardization in Haematology field study evaluating optimal interpretation methods for activated partial thromboplastin time and prothrombin time mixing studies
Gosselin, R.C., Moore, G.W., Kershaw, G.W., Montalvão, S. and Adcock, D.M. 2023. International Council for Standardization in Haematology field study evaluating optimal interpretation methods for activated partial thromboplastin time and prothrombin time mixing studies. Archives of Pathology & Laboratory Medicine. 148 (8), pp. 880-889. https://doi.org/10.5858/arpa.2023-0030-oa
Analytical dilemmas in lupus anticoagulant detection
Moore, G. 2023. Analytical dilemmas in lupus anticoagulant detection. Exploration of Immunology. 3, pp. 300-324. https://doi.org/10.37349/ei.2023.00104
ADAMTS13 activity measurement by ELISA and fluorescence resonance energy transfer assay
Moore, G., Llusa, M., Griffiths, M. and Binder, N. 2023. ADAMTS13 activity measurement by ELISA and fluorescence resonance energy transfer assay. in: Favaloro, E. and Gosselin, R. (ed.) Hemostasis and Thrombosis: Methods and Protocols New York, NY Humana.
ADAMTS13 activity: Screening test protocol
Moore, G., Griffiths, M. and Binder, N. 2023. ADAMTS13 activity: Screening test protocol. in: Favaloro, E. and Gosselin, R. (ed.) Hemostasis and Thrombosis: Methods and Protocols New York, NY Humana.
Lupus anticoagulant testing: Dilute prothrombin time (dPT)
Moore, G. 2023. Lupus anticoagulant testing: Dilute prothrombin time (dPT). in: Favaloro, E. and Gosselin, R. (ed.) Hemostasis and Thrombosis: Methods and Protocols New York, NY Humana.
Lupus anticoagulant testing: Taipan snake venom time with ecarin time as confirmatory test
Moore, G. 2023. Lupus anticoagulant testing: Taipan snake venom time with ecarin time as confirmatory test. in: Favaloro, E. and Gosselin, R. (ed.) Hemostasis and Thrombosis: Methods and Protocols New York, NY Humana.
ADAMTS13 antibody and inhibitor assays
Moore, G., Vetr, H. and Binder, N. 2023. ADAMTS13 antibody and inhibitor assays. in: Favaloro, E. and Gosselin, R. (ed.) Hemostasis and Thrombosis: Methods and Protocols New York, NY Humana.
Effects of regional citrate anticoagulation on thrombin generation, fibrinolysis and platelet function in critically ill patients receiving continuous renal replacement therapy for acute kidney injury: a prospective study
Fisher, R., Moore, G., Mitchell, M., Dai, L., Crichton, S., Lumlertgul, N. and Ostermann, M. 2022. Effects of regional citrate anticoagulation on thrombin generation, fibrinolysis and platelet function in critically ill patients receiving continuous renal replacement therapy for acute kidney injury: a prospective study. Annals of Intensive Care. 12 (1), pp. 1-11. https://doi.org/10.1186/s13613-022-01004-w
Activated partial thromboplastin time and prothrombin time mixing studies: current state of the art
Adcock, D., Moore, G., Montalvão, S., Kershaw, G. and Gosselin, R. 2022. Activated partial thromboplastin time and prothrombin time mixing studies: current state of the art. Seminars in Thrombosis and Hemostasis. https://doi.org/10.1055/s-0042-1756196
Added value of antiphosphatidylserine/prothrombin antibodies in the workup of thrombotic antiphospholipid syndrome: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies
Vandevelde, A., Chayoua, W., de Laat, B., Moore, G., Musiał, J., Zuily, S., Wahl, D. and Devreese, K. 2022. Added value of antiphosphatidylserine/prothrombin antibodies in the workup of thrombotic antiphospholipid syndrome: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. Journal of Thrombosis and Haemostasis. 20 (9), pp. 2136-2150. https://doi.org/10.1111/jth.15785
Snake venoms in diagnostic hemostasis and thrombosis
Moore, G. 2022. Snake venoms in diagnostic hemostasis and thrombosis. Seminars in Thrombosis and Hemostasis. 48 (02), pp. 145-160. https://doi.org/10.1055/s-0041-1732465
Semiquantitative interpretation of anticardiolipin and antiβ2glycoprotein I antibodies measured with various analytical platforms: communication from the ISTH SSC subcommittee on Lupus Anticoagulant/Antiphospholipid antibodies
Vandevelde, A., Chayoua, W., de Laat, B., Gris, J., Moore, G., Musiał, J., Zuily, S., Wahl, D. and Devreese, K. 2022. Semiquantitative interpretation of anticardiolipin and antiβ2glycoprotein I antibodies measured with various analytical platforms: communication from the ISTH SSC subcommittee on Lupus Anticoagulant/Antiphospholipid antibodies. Journal of Thrombosis and Haemostasis. 20 (2), pp. 508-524. https://doi.org/10.1111/jth.15585
International multicenter, multiplatform study to validate Taipan snake venom time as a lupus anticoagulant screening test with ecarin time as the confirmatory test: communication from the ISTH SSC subcommittee on Lupus Anticoagulant/Antiphospholipid antibodies
Moore, G., Jones, P., Platton, S., Hussain, N., White, D., Thomas, W., Rigano, J., Pouplard, C., Gray, E. and Devreese, K. 2021. International multicenter, multiplatform study to validate Taipan snake venom time as a lupus anticoagulant screening test with ecarin time as the confirmatory test: communication from the ISTH SSC subcommittee on Lupus Anticoagulant/Antiphospholipid antibodies. Journal of Thrombosis and Haemostasis. 19 (12), pp. 3177-3192. https://doi.org/10.1111/jth.15438
Clinical validation of an automated fluorogenic factor XIII activity assay based on isopeptidase activity
Leitner, M., Büchold, C., Pasternack, R., Binder, N. and Moore, G. 2021. Clinical validation of an automated fluorogenic factor XIII activity assay based on isopeptidase activity. International Journal of Molecular Sciences. 22 (3). https://doi.org/10.3390/ijms22031002
Applying index of circulating anticoagulant to mixing tests with lupus anticoagulant screen and confirm reagents can distinguish with high specificity between lupus anticoagulants and direct factor Xa inhibitors
Kumano, O., Amiral, J., Dunois, C., Peyrafitte, M. and Moore, G. 2021. Applying index of circulating anticoagulant to mixing tests with lupus anticoagulant screen and confirm reagents can distinguish with high specificity between lupus anticoagulants and direct factor Xa inhibitors. International Journal of Laboratory Hematology. 43 (4), pp. 771-778. https://doi.org/10.1111/ijlh.13571